Micronized Progesterone in HRT: Endometrial Protection and Safety

Micronized progesterone is bioidentical progesterone, chemically identical to the progesterone the ovaries make. The brand most often prescribed is Prometrium, an oral capsule. Micronized means the progesterone is ground into very fine particles so the body can absorb it from the gut, which earlier oral progesterone did not do well.

The FDA approved Prometrium to prevent endometrial hyperplasia in postmenopausal women who have not had a hysterectomy and who are taking estrogen, and to treat secondary amenorrhea, the absence of menstrual periods. Both are on-label uses. In menopausal hormone therapy its job is the first one: protecting the uterine lining.

The standard Prometrium capsule is suspended in peanut oil, which is why it carries a warning for anyone with a peanut allergy. A micronized progesterone capsule made without peanut oil exists for women who cannot take the peanut-oil form.

Micronized progesterone protects the uterus by opposing estrogen's effect on the lining. Estrogen tells the endometrial cells to multiply, which thickens the lining. Progesterone sends the opposite signal: it shifts the lining out of that growth state and keeps it thin and stable. In a natural cycle this is what triggers the lining to shed as a period.

In hormone therapy the same mechanism prevents the unchecked buildup that estrogen alone would cause. Without progesterone, that buildup is what drives hyperplasia and, in some women over time, cancer. With progesterone added on a schedule, the lining does not run away. This is the entire reason a progestogen is part of the regimen for a woman with a uterus, laid out further in this explainer on why progesterone is needed with estrogen.

Micronized progesterone and synthetic progestins both protect the uterus, but they are not the same molecule and they do not behave the same way elsewhere in the body. Micronized progesterone is identical to natural progesterone. A synthetic progestin, such as medroxyprogesterone acetate (MPA), is a man-made compound built to act on the progesterone receptor but with a different structure and different side effects.

This distinction sits at the center of how the menopause hormone evidence is read. The Women's Health Initiative, the trial that drove the boxed warnings and the drop in hormone use, gave women oral conjugated equine estrogens combined with MPA, not micronized progesterone (Rossouw 2002). So when people cite the WHI breast cancer numbers, they are describing a synthetic progestin regimen in older women, not bioidentical progesterone near menopause. The limits of the WHI for today's patients are covered in this look at the WHI study and the myths around it.

Micronized progesterone protects the uterine lining as well as a synthetic progestin does. The clearest evidence comes from the PEPI trial, a three-year randomized study of healthy postmenopausal women. Women given conjugated estrogen alone developed simple endometrial hyperplasia at a rate of about 28%, against under 1% on placebo. Women given estrogen plus cyclic micronized progesterone had hyperplasia rates close to placebo, the same protection seen with the MPA regimens (Writing Group for the PEPI Trial 1996).

PEPI also measured heart-disease risk factors, and here micronized progesterone had an edge. Estrogen raises HDL, the protective cholesterol. Adding MPA blunted that rise, while adding cyclic micronized progesterone preserved most of it: among women with a uterus, the estrogen-plus-micronized-progesterone arm had the most favorable HDL effect with no excess hyperplasia (Writing Group for the PEPI Trial 1995). So the two progestogens protected the lining equally, but the bioidentical one interfered less with estrogen's cholesterol benefit.

The breast cancer signal appears to differ between micronized progesterone and synthetic progestins, but the strongest evidence here is observational, not a randomized trial. In the French E3N cohort, which followed about 80,000 postmenopausal women, the choice of progestogen tracked with breast cancer risk. Estrogen combined with progesterone carried a relative risk of 1.00, meaning no measurable rise over never-use. Estrogen combined with other progestins carried a relative risk of 1.69 (Fournier 2008).

That difference is large, and it points the same way as the molecular reasoning. But a cohort study can show only an association. It cannot prove that the progestogen choice caused the difference, because the women were not randomly assigned and other factors may differ between groups. The honest reading is that micronized progesterone is linked to a lower breast cancer signal than synthetic progestins, that the link is biologically plausible, and that it is not proof of cause. It is one reason many clinicians prefer micronized progesterone, alongside its favorable cholesterol profile.

Micronized progesterone is taken at bedtime because it is sedating, and some women sleep better on it. The reason is a breakdown product. Once absorbed, progesterone is converted to allopregnanolone, a metabolite that acts on the GABA receptor in the brain in a way similar to a sedative, augmenting the brain's main calming signal (Paul 1992). That is what makes oral progesterone drowsy, so it is dosed in the evening rather than the morning.

The effect on sleep is real but measured. In a small randomized crossover study, 300 mg of oral micronized progesterone reduced the time postmenopausal women spent awake during the night, without dulling next-day thinking (Schussler 2008). Better sleep is a recognized side benefit for some women, not a primary reason to prescribe the drug. Its approved job remains protecting the uterine lining.

Most women tolerate micronized progesterone well, and its common side effects follow from the sedating mechanism. Drowsiness and dizziness are the most frequent, which is why the bedtime dose matters; taking it in the daytime can leave a woman groggy. Other reported effects include breast tenderness, mood changes, headache, and bloating.

The peanut oil in the standard capsule is a specific caution. Because Prometrium is suspended in peanut oil, it must not be used by anyone with a peanut allergy, and a peanut-free micronized progesterone formulation is the alternative in that case.

Progesterone is generally considered to carry less of the clot and breast concern attributed to synthetic progestins, but the serious risks of hormone therapy are driven mainly by the estrogen and the regimen as a whole. Those risks, and the November 2025 label change, are covered on the companion estradiol reference.

Micronized progesterone is not safe for everyone. It should not be used by anyone with:

• Known, suspected, or past breast cancer
• Undiagnosed abnormal vaginal bleeding
• Active or past venous blood clots, such as deep vein thrombosis or pulmonary embolism
• Active liver disease
• Known or suspected pregnancy
• Peanut allergy, for the peanut-oil capsule; a peanut-free formulation is the alternative

A clinician reviews these conditions before prescribing, because progesterone is part of a hormone regimen and the full history sets the balance of benefit and risk. That judgment belongs in the visit, with the prescriber seeing the whole picture.